Hemogenyx Pharmaceuticals (STU:5HU) Debt-to-Equity : 1.05 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Hemogenyx Pharmaceuticals Debt-to-Equity?

Hemogenyx Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.32 Mil. Hemogenyx Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €3.10 Mil. Hemogenyx Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €3.27 Mil. Hemogenyx Pharmaceuticals's debt to equity for the quarter that ended in Dec. 2023 was 1.05.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Hemogenyx Pharmaceuticals's Debt-to-Equity or its related term are showing as below:

STU:5HU' s Debt-to-Equity Range Over the Past 10 Years
Min: -3.62 Med: 1.05 Max: 1.83
Current: 1.05

During the past 9 years, the highest Debt-to-Equity Ratio of Hemogenyx Pharmaceuticals was 1.83. The lowest was -3.62. And the median was 1.05.

STU:5HU's Debt-to-Equity is ranked worse than
87.41% of 1072 companies
in the Biotechnology industry
Industry Median: 0.14 vs STU:5HU: 1.05

Hemogenyx Pharmaceuticals Debt-to-Equity Historical Data

The historical data trend for Hemogenyx Pharmaceuticals's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hemogenyx Pharmaceuticals Debt-to-Equity Chart

Hemogenyx Pharmaceuticals Annual Data

Trend

Feb15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-3.63

1.83

1.05

Hemogenyx Pharmaceuticals Semi-Annual Data
	Feb15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial												-	-	1.05	0.89	1.05

Competitive Comparison of Hemogenyx Pharmaceuticals's Debt-to-Equity

For the Biotechnology subindustry, Hemogenyx Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hemogenyx Pharmaceuticals's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hemogenyx Pharmaceuticals's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Hemogenyx Pharmaceuticals's Debt-to-Equity falls into.

Hemogenyx Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Hemogenyx Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.317	+	3.103)	/	3.272
	=	1.05

Hemogenyx Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.317	+	3.103)	/	3.272
	=	1.05

Hemogenyx Pharmaceuticals (STU:5HU) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Hemogenyx Pharmaceuticals Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Hemogenyx Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Hemogenyx Pharmaceuticals (STU:5HU) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hemogenyx Pharmaceuticals PLC (STU:5HU) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

HEMO:UK

Address

60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR

Website

https://www.hemogenyx.com

Hemogenyx Pharmaceuticals PLC is a operator of a biotechnology company intended to focus on the discovery, development, and commercialization of novel therapies and treatments for blood diseases, like leukaemia and lymphoma. The company's technologies aim to change the way in which bone marrow/hematopoietic stem cell transplants are performed and improve their efficacy, its three distinct products include an immunotherapy product for the treatment of relapsed/refractory acute myeloid leukaemia (AML) and patient conditioning, the bi-specific antibody, for the treatment of AML and a community-based rehabilitation / Biomedical engineering platform, enabling users to generate treatments for existing and emerging viral infections.

Hemogenyx Pharmaceuticals (STU:5HU) Headlines

No Headlines